Execution on the expansion road — can Q2 sustain 19%+ growth?
Park Medi World reports Q2 FY27 (Sep-end) on Nov 13, with the Street watching for sustained revenue momentum and margin hold amid aggressive bed capacity additions. We've seen 19–20% growth run-rate in Q1; the test is whether recent acquisitions and new hospitals keep pace.
The setup: sustained growth or margin squeeze?
Park Medi World enters Q2 FY27 with strong Q1 tailwinds: 19% revenue growth to ₹476 Cr and 35% profit growth to ₹88.6 Cr. The Street is watchful—this is no longer IPO story, it's an execution story. With three major initiatives in flight (Mehar Zirakpur acquisition, Kanpur hospital O&M, Prayagraj PPP), the question is whether operational leverage holds or if acquisition integration costs pressure margins.
~₹475–485 Cr
If on Q1 trajectory (19% YoY growth); acquisition add-back timing key
~22%
Q1 showed steady margins; watch for acquisition synergies
~₹88–95 Cr
35% YoY growth in Q1; sustainability hinge on bed utilisation
~4,200–4,300
Mehar Zirakpur (120-bed) + organic growth; Kanpur/Prayagraj still in setup
What good vs weak looks like
A strong print: Revenue ₹485+ Cr (matching or exceeding 19% YoY); EBITDA margin ≥22% (showing acquisition synergies and pricing power); profit ≥₹90 Cr (sustaining 30%+ growth). Management signals Q3 timing for Kanpur ramp and clarity on Prayagraj PPP execution.
A weak print: Revenue < ₹470 Cr (slowing below 17% YoY, signalling demand softness or acquisition integration drag); margins compressing below 21% (operational friction); profit < ₹85 Cr. Any guidance miss on capacity additions or delays in Kanpur operationalisation would test confidence in the 5,740-bed target by FY28.
Is the company on track?
Yes, momentum is intact, but execution risk is rising. Q1 FY27 delivered 19% revenue growth and 35% profit growth—well-aligned with management's stated ambition to add 1,490 beds in 2026 and reach 5,740 beds by March 2028. However, the company is now juggling three major expansions simultaneously: the Mehar Zirakpur acquisition (₹107 Cr, announced Aug 2026), the Kanpur 300-bed O&M agreement (28-year term, signed Sep 2026), and the Prayagraj 550-bed PPP project (in-progress). Successfully integrating Zirakpur while bringing Kanpur online and securing Prayagraj permits will test both capital discipline and operational bandwidth. If all three contribute as planned, the runway for 18–22% revenue growth looks intact; if any slips, the Street could reprrice.
What the Street says
Since last quarter: what's changed
1 · Mehar Hospital Zirakpur acquisition approved (Aug 3, 2026)
Board approved acquisition of 120-bed Mehar Hospital in Zirakpur for ₹107 Cr in cash. Integration should be visible in Q2 results. Adds established revenue stream and operational know-how.
2 · Kanpur 300-bed hospital O&M agreement signed (Sep 16, 2026)
Wholly-owned subsidiary Aggarwal Hospital and Research Services signed 28-year O&M agreement with Axis Educational Society for a 300-bed hospital in Kanpur. Ramp expected Q3/Q4 FY27; modest impact on Q2 numbers.
3 · Prayagraj 550-bed PPP project in progress (Aug 31, 2026)
Board approved incorporation of wholly-owned subsidiary for 550-bed multi-super-speciality hospital in Prayagraj under PPP with Municipal Corporation. Capital-light model; long-term play but not material to Q2.
4 · Income Tax Department verification completed (Oct 12–17, 2026)
Routine verification at Park Medi World and subsidiary premises by Income Tax Department. Company disclosed full cooperation; no penalties or issues flagged. Routine regulatory compliance.
5 · Management personnel appointment (Nov 6, 2026)
Mr. Abhishek Kumar (Head of Accounts) designated as Senior Management Personnel (SMP). Minor housekeeping; no change to operational leadership.
6 · Board meeting rescheduled to Nov 13, 2026
Originally scheduled for Nov 9, the Board meeting to approve Q2 FY27 financial results was moved to Nov 13 to allow additional review time. Standard move; no concern flagged.
The ownership lens
Promoter holding stands steady at 82.89% (unchanged from Q1). DII ownership ticked down slightly to 8.95% (from 9.25% in FY26 Q4), while FII presence remains minimal at 0.82%. The stable promoter stake reflects founder commitment; the dip in DII may signal some profit-taking on the stock's 82% YTD surge, though it's not a red flag. No pledge activity or insider trading flagged in recent filings.
Technical backdrop
Stock price ₹251.39 trades NEUTRAL to technicals: above the 20-day SMA (₹232.6) but below the 50-day SMA (₹261.31) and above the 200-day SMA (₹241.85). RSI sits at 56.5 (neutral), and volume is trending downward—typical pre-result quiet. The stock is 17.6% off its all-time high of ₹305 set recently, giving room for surprise upside on a strong result.
Park Medi World enters Q2 FY27 results with solid momentum: 19% revenue growth, 35% profit growth, and a clear expansion blueprint (1,490 new beds targeted in 2026). The Street is bullish (Strong Buy consensus, ₹362–406 targets), but execution is the watchword. Three major projects—Mehar Zirakpur acquisition, Kanpur hospital O&M, Prayagraj PPP—will test both capital discipline and operational focus. On Nov 13, watch for: (1) whether revenue sustains ₹475+ Cr (on-plan trajectory) or dips below ₹470 Cr (demand softness); (2) margin hold at ≥22% EBITDA (synergies visible) or compression below 21% (integration drag); and (3) management's Q3/Q4 guidance on Kanpur ramp and Prayagraj PPP timeline—the credibility of the 5,740-bed target hinges on these delivery dates.
Park Medi World Q2: consolidated PAT down 31% YoY on margin squeeze, revenue up 25%
PAT -30.8% YoY · revenue +24.6% · margins compressing
₹511.03 Cr
+24.6% YoY
₹54.46 Cr
-30.8% YoY
10.46%
₹1.26
On a consolidated basis — the primary basis here, since the standalone entity is just the listed holding company — Park Medi World's Q2 FY27 revenue from operations grew 24.6% YoY to ₹511.0 Cr (+7.4% QoQ from ₹475.7 Cr), but net profit fell 30.8% YoY to ₹54.5 Cr (₹52.2 Cr to owners of the parent, ₹2.3 Cr to non-controlling interests), down 38.5% QoQ from ₹88.6 Cr in Q1 FY27. There were no exceptional items in either the current or comparative periods, so this is a genuine operating-margin story, not an accounting one.
Q2 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
Net profit margin compressed to 10.5% from 18.8% a year ago and 18.3% last quarter; operating margin (PBT plus depreciation and finance costs, on total income) fell to roughly 21.4% from ~28.9% YoY and ~27.7% QoQ. The squeeze is broad-based rather than one line: cost of materials/services consumed rose 64.2% YoY to ₹116.4 Cr, employee benefit expenses rose 29.5% YoY to ₹100.2 Cr, other expenses rose 36.7% YoY to ₹122.5 Cr and depreciation rose 40.2% YoY to ₹20.9 Cr — all outpacing 24.6% revenue growth, consistent with newly consolidated capacity (V3 Healthcare's 330-bed Rudrapur hospital, acquired and launched August 2, 2026) carrying cost ahead of its revenue contribution.
The stock went into the print at ₹243, up 0.7% over the past month of trading.
FY'27: Revenue ₹2,080 Cr (24% YoY), EBITDA ₹530 Cr (26-27% margin), PAT ₹360 Cr. Capacity to reach 4,740 beds by FY'27 end, 5,740 beds by FY'28. CGHS rate benefit 7-7.5% (Oct 2025 hike); payor mix to shift to 70:30 (government:private/TPA) over 12-18 months.
— This quarter: missed
Management's FY27 guidance from the August concall called for ₹2,080 Cr revenue, 26-27% EBITDA margin and ₹360 Cr PAT. H1 FY27 revenue of ₹986.7 Cr is 47.4% of that full-year target — broadly on track for a second-half-weighted year — but H1 PAT of ₹143.0 Cr is only 39.7% of the ₹360 Cr goal, and H1 EBITDA margin of ~24.8% already trails the guided band before this quarter's sharper 21.4% print; profitability guidance looks under pressure even as the topline tracks. No analyst previews or consensus estimates for this specific quarter turned up in search — the result was board-approved and announced the same day, November 13, 2026 — so the print cannot be benchmarked against street expectations, and management has issued no press release beyond the regulatory intimation.
W1
H2 FY27 margin recovery toward the guided 26-27% EBITDA band, from ~21.4% this quarter
W2
PAT pace: H1 FY27 PAT of ₹143.0 Cr needs ~₹217 Cr in H2 to hit the ₹360 Cr FY27 guidance
W3
Integration/ramp of newly added capacity (330-bed Rudrapur, 550-bed Prayagraj PPP, 300-bed Kanpur from April 2027, Mehar Mediserve) toward the 4,740-bed FY27 target